Bausch + Lomb Corporation (BLCO): Price and Financial Metrics
BLCO Price/Volume Stats
| Current price | $18.49 | 52-week high | $19.96 |
| Prev. close | $18.51 | 52-week low | $12.20 |
| Day low | $18.39 | Volume | 261,711 |
| Day high | $18.67 | Avg. volume | 400,856 |
| 50-day MA | $17.74 | Dividend yield | N/A |
| 200-day MA | $16.42 | Market Cap | 6.48B |
BLCO Stock Price Chart Interactive Chart >
BLCO Stock Summary
- With a one year PEG ratio of 0.47, BAUSCH & LOMB CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.47% of US stocks.
- BAUSCH & LOMB CORP's stock had its IPO on May 6, 2022, making it an older stock than merely 0.3% of US equities in our set.
- BAUSCH & LOMB CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -38.6%, greater than the shareholder yield of only 12.65% of stocks in our set.
- Stocks that are quantitatively similar to BLCO, based on their financial statements, market capitalization, and price volatility, are NLS, HUN, BELFA, MTRN, and PLPC.
- To check out BAUSCH & LOMB CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001860742.
BLCO Valuation Summary
- In comparison to the median Healthcare stock, BLCO's EV/EBIT ratio is 370.83% higher, now standing at 56.5.
- Over the past 13 months, BLCO's price/earnings ratio has gone down 102.9.
Below are key valuation metrics over time for BLCO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BLCO | 2023-05-23 | 1.8 | 1.0 | -64.4 | 56.5 |
| BLCO | 2023-05-22 | 1.8 | 1.0 | -65.5 | 57.3 |
| BLCO | 2023-05-19 | 1.8 | 1.0 | -65.5 | 57.2 |
| BLCO | 2023-05-18 | 1.8 | 1.0 | -65.4 | 57.2 |
| BLCO | 2023-05-17 | 1.8 | 1.0 | -65.7 | 57.4 |
| BLCO | 2023-05-16 | 1.7 | 0.9 | -63.4 | 55.9 |
Bausch + Lomb Corporation (BLCO) Company Bio
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Latest BLCO News From Around the Web
Below are the latest news stories about BAUSCH & LOMB CORP that investors may wish to consider to help them evaluate BLCO as an investment opportunity.
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's MeetingVAUGHAN, Ontario, June 08, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that researchers will present the results of 11 scientific poster presentations involving the company’s consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry’s Meeting e-posters Virtual Event, which is taking place from June 13-14, 2023. In ad |
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United StatesVAUGHAN, Ontario, June 06, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Biotrue® Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to lubricate and rewet soft contact lenses, including daily disposables, and rigid gas permeables. |
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United StatesVAUGHAN, Ontario, June 05, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE® Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology™ for all-day comfort and the company’s unique 3-Zone Progressive™ design, the new lens addresses the dynamic vision |
Bausch + Lomb Announces Key Leadership ChangesVAUGHAN, Ontario, June 01, 2023--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP, Vision Care; will join the executive management team of the Company reporting directly t |
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye DiseaseVAUGHAN, Ontario & HEIDELBERG, Germany, May 18, 2023--FDA approves MIEBO (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease. |
BLCO Price Returns
| 1-mo | 0.76% |
| 3-mo | 16.29% |
| 6-mo | 21.56% |
| 1-year | 26.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 19.21% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...